Clarity Pharmaceuticals , a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, announced the completion of recruitment for the Phase I PROPELLER diagnostic trial evaluating its 64Cu-SAR-bisPSMA product candidate in patients with untreated, confirmed prostate cancer, scheduled for radical prostatectomy. A total of 30 participants have been enrolled in the trial across multiple clinical sites in Australia under the supervision of Lead Principal Investigator, Prof Louise Emmett, at St Vincent’s Hospital in Sydney.

Clarity expects to report topline results data from the PROPELLER trial in the coming months following the completion of study assessments for all participants and once data analysis activities are finalized. The data will inform a planned registrational Phase III trial in participants with untreated, confirmed prostate cancer in the US.

To read more please visit:

Recruitment complete for Clarity’s PROPELLER prostate cancer diagnostic trial

Source: Clarity